NIH

Advanced Lateral Flow Conference 2024 Agenda Now Available for Download

Retrieved on: 
Friday, January 19, 2024
LFA, BBC, ITAP, Lunch, SAN, Education minister, Initiative, Team leader, Conference, COVID-19, Acceleration, NIH, Tutoring

SAN DIEGO, Jan. 19, 2024 /PRNewswire/ -- The organizers of the Advanced Lateral Flow Conference (ALFC) 2024 are excited to announce that the full conference agenda is now available for download. This year's conference, set to take place on February 12-14, at the Hard Rock Hotel San Diego, promises to be an enriching experience for professionals in the lateral flow industry.

Key Points: 
  • SAN DIEGO, Jan. 19, 2024 /PRNewswire/ -- The organizers of the Advanced Lateral Flow Conference (ALFC) 2024 are excited to announce that the full conference agenda is now available for download.
  • This year's conference, set to take place on February 12-14, at the Hard Rock Hotel San Diego, promises to be an enriching experience for professionals in the lateral flow industry.
  • The ALFC 2024 is a premier event that brings together experts, innovators, and thought leaders in the field of lateral flow technology.
  • Closing Reception and Awards Ceremony: Join us for our final evening networking event and the announcement of the winners of the prestigious 2024 Advanced Lateral Flow Conference Awards.

Global Hyperspectral Imaging Systems Market Analysis Report 2023-2030: Precision and Clarity Drive Growth, Technological Breakthroughs Power Adoption, Growing Demand Across Industries

Retrieved on: 
Wednesday, January 17, 2024
Care Act 2014, Research, Affordable Care Act, Diagnosis, Intelligence, Hyperspectral imaging, Google Images, Growth, Defense, Investment, NIH, USD, Food industry, Health, Plant, Night vision, Bangladesh Technical Education Board, Medical imaging

The increasing utilization of hyperspectral imaging across various industries, including research and development, healthcare, defense, the food industry, night vision, and remote sensing, is poised to generate substantial market demand.

Key Points: 
  • The increasing utilization of hyperspectral imaging across various industries, including research and development, healthcare, defense, the food industry, night vision, and remote sensing, is poised to generate substantial market demand.
  • In contrast to conventional imaging and detection methods, hyperspectral imaging enhances sensitivity and differentiation by amalgamating digital imaging with spectroscopy.
  • The Hyperspectral Imaging Systems Market research report provides an in-depth overview of the industry including market segmentation by product, technology, application, end-user, and region.
  • Analysis of the global market with a special focus on high-growth applications in each vertical and fast-growing market segment.

Neuvivo Names Dr. James Kovach as Chief Medical Affairs Officer

Retrieved on: 
Wednesday, January 17, 2024
JD, ALS, MD, UC, Devon Walker, Biotechnology, Athlete, PALO, Neck, Buck, Ageing, Football, Communication, New Orleans Saints, Amyotrophy, Disease, NIH, Spine, Doctor of Philosophy, Military personnel, Research, NFL, Pharmaceutical industry

PALO ALTO, Calif., Jan. 17, 2024 /PRNewswire/ -- Neuvivo, a private, late-clinical-stage biopharmaceutical company focused on creating and delivering advanced treatments for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases, today announced the appointment of Dr. James Kovach, MD, JD, as its new Chief Medical Affairs Officer.

Key Points: 
  • PALO ALTO, Calif., Jan. 17, 2024 /PRNewswire/ -- Neuvivo, a private, late-clinical-stage biopharmaceutical company focused on creating and delivering advanced treatments for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases, today announced the appointment of Dr. James Kovach, MD, JD, as its new Chief Medical Affairs Officer.
  • Ari Azhir, PhD, Founder and CEO of Neuvivo, commented, "Dr. Kovach's appointment to our leadership team represents a significant milestone for Neuvivo.
  • "I feel the breadth of my experiences have been a training set for this moment," said Dr. Kovach, Chief Medical Affairs Officer, Neuvivo.
  • At Neuvivo, Dr. Kovach will lead key global functions related to the development and commercialization of Neuvivo's therapeutic pipeline, including medical affairs and the presentation and communication of clinical and scientific information about Neuvivo's lead drug candidate, NP001, to key stakeholders, including the medical community, patient groups, payers and others.

Green Virgin Products' Moringa Oil Wins Award for Best Natural Beauty Product for 2024

Retrieved on: 
Wednesday, January 17, 2024
Seed, Nutrient, Ayurveda, Health, Moringa (genus), Cytokinin, Moringa, Zeatin, History, Anti-inflammatory, NIH, Protein, Ageing, Antioxidant, Cosmetics

NEW YORK, Jan. 17, 2024 /PRNewswire/ -- HealthXWire has recognized Green Virgin Products' Moringa Oil, the all-natural, certified organic, non-toxic skin and hair care treatment, with the Best Natural Beauty Product for 2024 award.

Key Points: 
  • NEW YORK, Jan. 17, 2024 /PRNewswire/ -- HealthXWire has recognized Green Virgin Products' Moringa Oil, the all-natural, certified organic, non-toxic skin and hair care treatment, with the Best Natural Beauty Product for 2024 award.
  • Green Virgin Moringa Oil is extracted from the seeds of the moringa oleifera tree, found in tropical and subtropical countries around the world; its nutrient richness has helped the plant survive drought and harsh environmental conditions.
  • Green Virgin is proud to source its Moringa Oil exclusively from small organic growers.
  • The company's Moringa Oil is always 100% pure, extra virgin, cold-pressed, certified organic, and free of preservatives and chemicals.

United States Single Cell Genomics and Proteomics Growth Opportunities: The Integration of Multi-Omics Data to Drive the Development of Personalized Medicine

Retrieved on: 
Tuesday, January 16, 2024
Artificial intelligence, Research, Proteomics, Single-cell analysis, Genomics, Software, NIH, Machine learning, Data analysis, Single cell sequencing, Bangladesh Technical Education Board, Growth, Fine chemical

DUBLIN, Jan. 16, 2024 /PRNewswire/ -- The "Growth Opportunities in Single Cell Genomics and Proteomics in the United States" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 16, 2024 /PRNewswire/ -- The "Growth Opportunities in Single Cell Genomics and Proteomics in the United States" report has been added to ResearchAndMarkets.com's offering.
  • It began as a niche, specialized technology with few companies offering solutions, which then became commonly used in academia.
  • The United States represents about 60% of the total market and is on track to increase about 12% to 16% annually.
  • These novel tools encourage the development of software and data analysis solutions to help researchers interpret data.

Stalicla Secures $17.4 Million in Series B Financing to Propel Precision Neuro Advancements

Retrieved on: 
Tuesday, January 16, 2024
ASD, Patient, Neurology, Suds, Autism spectrum, NAM, Substance use disorder, Glutamate (neurotransmitter), NIH, Myenteric plexus, Medicine, Pharmaceutical industry

Geneva, Switzerland, January 16th, 2024 – Stalicla SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders, announces the successful completion of the first closing of its Series B financing round, securing $17.4 million.

Key Points: 
  • Geneva, Switzerland, January 16th, 2024 – Stalicla SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders, announces the successful completion of the first closing of its Series B financing round, securing $17.4 million.
  • Led by SPRIM Global Investments Pte, Ltd, with key participation from core investors, this funding includes a $3.8 million credit facility.
  • Alongside these key developments, Stalicla will further strengthen the package supporting its second precision ASD asset, STP2.
  • Lynn Durham, CEO of Stalicla commented: “This financial backing underscores Stalicla's role as a trailblazer in the neuro precision space with first applications in precision psychiatry.

Sensydia Completes Fifth Study for Heart-Sound AI

Retrieved on: 
Tuesday, January 16, 2024
Cardiology, University, Biotechnology, Education, Technology, Health, Medical Devices, Research, Artificial Intelligence, Science, Clinical Trials, Knowledge, Artificial intelligence, Patient, Associate, MD, Life, Multimedia, Cardiac output, Heart failure, Echocardiography, Algorithm, Principal investigator, University of Minnesota, NIH, FDA, UMN, CPS, Ronald Reagan, Diagnosis, Pulmonary hypertension, Medical device

Non-invasive cardiac assessment company Sensydia announced today that it has completed its 50-subject development study at the University of Minnesota (UMN).

Key Points: 
  • Non-invasive cardiac assessment company Sensydia announced today that it has completed its 50-subject development study at the University of Minnesota (UMN).
  • In January 2022, Sensydia announced that CPS was granted Breakthrough Device Designation by the United States Food and Drug Administration (FDA).
  • Sensydia plans to use data from this 50-subject study to develop the CPS pulmonary pressure algorithms.
  • The achievement of this 50-subject milestone comes at a time when Sensydia is actively executing Phase I of its new NIH award.

Benevis White Paper Highlights Harmful Economic Impact of Poor Oral Health

Retrieved on: 
Tuesday, January 16, 2024
Public Policy, Government, Health, Parenting, Children, Family, Consumer, Dental, Advocacy Group Opinion, SDOH, Risk, Medicaid, CHIP, Senate, Dental care, Dentist, American Dental Association, NIH, Health policy, Workforce, Bangladesh Technical Education Board, Education, Dentistry, Health insurance

The Benevis white paper explores the ripple effect of poor oral health, extending beyond the healthcare system to impact education, workforce productivity, and economic disparities.

Key Points: 
  • The Benevis white paper explores the ripple effect of poor oral health, extending beyond the healthcare system to impact education, workforce productivity, and economic disparities.
  • "As an industry, we recognize that preventive care is critical to curbing the long-term consequences – economically and physically – of neglected oral health.
  • The consequences of poor oral health extend to significant healthcare costs, indirect costs, and emotional tolls.
  • Benevis aims to bring attention to the pressing issue of poor oral health's economic impact, advocating for high-quality, accessible dental care, comprehensive coverage, and a focus on preventive measures to alleviate the burden on both individuals and the healthcare system.

Manatt Expands National Health Care Offerings With Leading Health Policy Strategist in D.C.

Retrieved on: 
Tuesday, January 16, 2024
Professional Services, Health, Other Professional Services, Legal, Practice Management, Consulting, Manatt, Phelps & Phillips, LLP, Policy, Medicare, Biotechnology, Macs, CDC, Health policy, CMS, NIH, HHS, Congress, National Institutes of Health, Private sector, Bangladesh Technical Education Board

“Heide brings a vast and technical skill set within health policy that will benefit clients looking to implement cutting-edge initiatives as they navigate the ever-evolving regulatory landscape,” said Donna L. Wilson , CEO and Managing Partner of Manatt.

Key Points: 
  • “Heide brings a vast and technical skill set within health policy that will benefit clients looking to implement cutting-edge initiatives as they navigate the ever-evolving regulatory landscape,” said Donna L. Wilson , CEO and Managing Partner of Manatt.
  • “Heide is a highly skilled health policy leader who is extremely well versed in coding and developing effective market launch programs, having led numerous commercialization projects from the front lines,” said Manatt Health Leader Bill Bernstein .
  • Bajnrauh has also worked on regulatory and congressional issues involving health policy at both the agency and legislative levels.
  • “Like Manatt, I have always been dedicated to helping improve the health care industry to advance high-quality care, and I look forward to continuing this work at the national, state and local levels alongside the team.”

Dr. Ghassan Kassab Joins Anuncia Medical's Board, Elevating Future Product Innovation

Retrieved on: 
Tuesday, January 16, 2024
Entrepreneurship, Senior, Therapy, Biological engineering, CSF, Engineering, University, Hydrocephalus, Chemical substance, NIH, Purdue University, FDA, Medtronic, Cerebrospinal fluid, General partnership, Chemical engineering

In this role, Dr. Ghassan will provide guidance and support for the continued commercialization of the ReFlow™ Mini Flusher Device and future innovation to significantly improve patient access and care.

Key Points: 
  • In this role, Dr. Ghassan will provide guidance and support for the continued commercialization of the ReFlow™ Mini Flusher Device and future innovation to significantly improve patient access and care.
  • Dr. Ghassan joins an active, expert group of industry leaders committed to helping Anuncia redefine clinical approaches to cerebrospinal fluid dysfunctions, including hydrocephalus.
  • Dr. Kassab is a successful serial entrepreneur who brings decades of academic and industry experience to Anuncia.
  • We are thrilled that Dr. Kassab has joined our Board to help drive these future innovations," stated Elsa Chi Abruzzo, CEO of Anuncia.